Meda Drug Patent Portfolio
Meda owns 2 orange book drugs protected by 4 US patents Given below is the list of Meda's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8071073 | Compositions comprising azelastine and methods of use thereof | 04 Jun, 2028 | Active |
| US8518919 | Compositions comprising azelastine and methods of use thereof | 22 Nov, 2025 | Expired |
| US6024981 | Rapidly dissolving robust dosage form | 09 Apr, 2018 | Expired |
| US6221392 | Rapidly dissolving robust dosage form | 09 Apr, 2018 | Expired |
Latest Legal Activities on Meda's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Meda.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Maintenance Fee Reminder Mailed | 10 Nov, 2025 | US9919050 |
| Expire Patent | 29 Sep, 2025 | US8518919 |
| Maintenance Fee Reminder Mailed | 14 Apr, 2025 | US8518919 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 23 May, 2023 | US8071073 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 07 Sep, 2021 | US9919050 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 Feb, 2021 | US8518919 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 May, 2019 | US8071073 (Litigated) |
| Post Issue Communication - Certificate of Correction | 23 May, 2018 | US9919050 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 20 Mar, 2018 | US9919050 |
|
Recordation of Patent Grant Mailed
Critical
| 20 Mar, 2018 | US9919050 |
|
Email Notification
Critical
| 01 Mar, 2018 | US9919050 |
|
Issue Notification Mailed
Critical
| 28 Feb, 2018 | US9919050 |
| Dispatch to FDC | 07 Feb, 2018 | US9919050 |
|
Application Is Considered Ready for Issue
Critical
| 02 Feb, 2018 | US9919050 |
|
Issue Fee Payment Received
Critical
| 01 Feb, 2018 | US9919050 |
Meda's Drug Patent Litigations
Meda's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 07, 2014, against patent number US8071073. The petitioner Impax Laboratories, Inc., challenged the validity of this patent, with Meda Pharmaceuticals Inc. as the respondent. Click below to track the latest information on how companies are challenging Meda's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8071073 | May, 2014 |
Institution Denied
(29 Jul, 2014)
| Meda Pharmaceuticals Inc. | Impax Laboratories, Inc. |
Meda's Family Patents
Clinical Trials
Recent Clinical Trials by Meda:
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Alternative Antibiotics for Syphilis | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | NA |
COMPLETED
(Jul 1, 2026)
| PHASE3 |
| Repurposing Clinically Approved Drugs for Yaws With an Insight Into the Cutaneous Ulcer Disease Syndrome (Trep-AByaws) | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | NA |
COMPLETED
(Jul 1, 2026)
| PHASE3 |
| Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC) | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE2 |
| Ulcer Plants: Highly Accessible Plant Antiseptics for Use in Remote Areas of PNG - Second Trial | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE2 |
| Safety and Impact of Baricitinib on Cell Surivival Pathways, HIV-1 Reservoir and Inflamation in People With HIV-1 | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | NA |
COMPLETED
(Jun 1, 2026)
| PHASE2 |
| Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics | medac GmbH | NA |
COMPLETED
(May 1, 2026)
| PHASE1 |
| PK, PD, Safety and Immunogenicity of Spectrila in Adults With Acute B-cell Lymphoblastic Leukaemia | medac GmbH | NA |
TERMINATED
(Mar 1, 2026)
| PHASE2 |
Meda Drug List
Given below is the complete list of Meda's drugs and the patents protecting them.
1. Astepro
Astepro is protected by 2 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8071073 | Compositions comprising azelastine and methods of use thereof |
04 Jun, 2028
(1 year, 7 months from now)
| Active |
| US8518919 | Compositions comprising azelastine and methods of use thereof |
22 Nov, 2025
(10 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Astepro's drug page
2. Reglan Odt
Reglan Odt is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6024981 | Rapidly dissolving robust dosage form |
09 Apr, 2018
(8 years ago)
| Expired |
| US6221392 | Rapidly dissolving robust dosage form |
09 Apr, 2018
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Reglan Odt's drug page